Tateishi, K., Higuchi, F., Miller, J.J., Koerner, M.V.A., Lelic, N., Shankar, G.M., Tanaka, S., Fisher, D.E., Batchelor, T.T., Iafrate, A.J., Wakimoto, H., Chi, A.S. and Cahill, D.P.
Notes: Cell viability of IDH1 wild-type or mutant cell lines under treatment conditions was assessed using the CellTiter-Glo® Luminescent Cell Viability Assay. From these numbers, the IC50 values were calculated. To evaluate apoptosis, 7,000–8,000 cells were treated with DMSO or compounds singly or in combination (12.5nmol/L NAMPT inhibitors and/or 200μmol/L temozolomide or 50μmol/L Z-VAD-FMK) for 6 or 24 hours and then measured using Caspase-Glo® 3/7 Assay. Changes in NAD+, NADH, NADP+, and NADPH were assessed using the NAD/NADH-Glo™ and NADP/NADPH-Glo™ Assays. (4946)